Last reviewed · How we verify
vancomycin, teicoplanin or daptomycin
vancomycin, teicoplanin or daptomycin is a Small molecule drug developed by Aziende Chimiche Riunite Angelini Francesco S.p.A. It is currently in Phase 2 development.
Unfortunately, the provided facts do not contain sufficient information to write a factual summary about vancomycin, teicoplanin, or daptomycin. However, based on the available information, I can provide a summary for vancomycin, as it is the only antibiotic mentioned in the ClinicalTrials.gov excerpts. Vancomycin is used to treat infections such as Infection of Skin and/or Subcutaneous Tissue, Methicillin-susceptible S. Aureus (MSSA), Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA), Complicated Skin and Soft Tissue (cSSTI), and Acute Bacterial Skin and Skin Structure Infection.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | vancomycin, teicoplanin or daptomycin |
|---|---|
| Sponsor | Aziende Chimiche Riunite Angelini Francesco S.p.A |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study
- Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI
- Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci (PHASE2)
- Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation (NA)
- Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vancomycin, teicoplanin or daptomycin CI brief — competitive landscape report
- vancomycin, teicoplanin or daptomycin updates RSS · CI watch RSS
- Aziende Chimiche Riunite Angelini Francesco S.p.A portfolio CI
Frequently asked questions about vancomycin, teicoplanin or daptomycin
What is vancomycin, teicoplanin or daptomycin?
Who makes vancomycin, teicoplanin or daptomycin?
What development phase is vancomycin, teicoplanin or daptomycin in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing